EVMN
Evommune, Inc.
NYSE · Healthcare · Biotechnology · US
$5.27
+1.93%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -66.7%
- EBITDA
- +66.1%
- EPS
- -39.5%
Three-year CAGR
- Revenue
- +61.2%
- EBITDA
- -3.0%
- EBIT
- -15.8%
- Net income
- -3.1%
- EPS
- +4.0%
- Free cash flow
- -31.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026